NeuroSense & Lonza Partner on Neurodegenerative Disease Biomarkers
Ticker: NRSNW · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, biomarkers, neurodegenerative-disease
TL;DR
NeuroSense teams up with Lonza to find new biomarkers for Alzheimer's & ALS.
AI Summary
On April 9, 2024, NeuroSense Therapeutics Ltd. announced a collaboration with Lonza to identify exosome-based biomarkers. This partnership aims to advance treatments and diagnostics for neurodegenerative diseases.
Why It Matters
This collaboration could lead to new diagnostic tools and more effective treatments for debilitating neurodegenerative conditions.
Risk Assessment
Risk Level: medium — The success of this collaboration is dependent on the identification of effective biomarkers, which is a complex and uncertain process in drug development.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer and collaborator
- Lonza (company) — Collaborator
- April 9, 2024 (date) — Date of press release
FAQ
What is the primary goal of the collaboration between NeuroSense Therapeutics and Lonza?
The primary goal is to identify exosome-based biomarkers to advance treatments and diagnostics for neurodegenerative diseases.
What type of diseases is this collaboration focused on?
The collaboration is focused on neurodegenerative diseases.
When was the press release announcing this collaboration issued?
The press release was issued on April 9, 2024.
What is the role of Lonza in this partnership?
Lonza is collaborating with NeuroSense Therapeutics to identify exosome-based biomarkers.
What is NeuroSense Therapeutics Ltd.'s primary business area?
NeuroSense Therapeutics Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 202 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-04-09 08:32:26
Filing Documents
- ea0203546-6k_neuro.htm (6-K) — 10KB
- ea020354601ex99-1_neuro.htm (EX-99.1) — 24KB
- 0001213900-24-031353.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: April 9, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2